首页 > 市场调查报告书 > 製药

精神疾病

市场调查报告书

商品编码

1134516

幻觉剂的全球市场:现状分析与预测(2022年～2028年)

Psychedelic Drugs Market: Current Analysis and Forecast (2022-2028)

出版日期: 2022年09月01日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 154 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

全球幻觉剂的市场规模在预测期间(2022年～2028年)中预计将以约6％的年复合成长率成长。公众对心理健康的认识不断提高，寻找新疗法的研发活动增加，以及精神疾病病例数量的激增正在推动致幻剂市场的增长。

本报告提供全球幻觉剂市场的相关调查，提供市场洞察，市场趋势，竞争模式，企业概要等全面性资讯。

Global Psychedelic Drugs Market is expected to grow at a significant rate of around 6% during the forecast period. Psychedelic drugs are a class of psychoactive drugs that can produce changes in perception, mood, and cognitive processes. The global psychedelic drugs market is anticipated to witness an uptick owing to the growing awareness among the population regarding mental health, increasing research & development activities for exploring novel treatment options, and a rapid increase in the number of cases of depression, stress, and other mental disorders. For instance, in 2019, nearly 264 million people were suffering from depression and about 50 million people were suffering from dementia across the globe. Also, according to the National Council for Mental Wellbeing, almost half of the adults (46.4%) will suffer from a mental health disorder in their lifetime, and nearly 43.8 million adults (18 years or older) experience a mental illness at any one year. Furthermore, the increasing need for handling excess stress, anxiety, and other mental disorders along with the availability of off-label drugs in the market are also some of the factors that are positively influencing the psychedelic drugs market across the globe.

Jazz Pharmaceuticals plc, Hikma Pharmaceuticals plc, Celon Pharma SA, Cybin Corp., Pfizer Inc., Numinus Wellness Inc., F. Hoffmann-La Roche Ltd., Avadel Pharmaceuticals PLC, PharmaTher Inc., NRX Pharmaceuticals Inc. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with drugs.

Insights Presented in the Report:

"Amongst drugs, LSD category to witness higher CAGR during the forecast period"

Based on drugs, the psychedelic drugs market is segmented into lysergic acid diethylamide (LSD), gamma-hydroxybutyric acid (GHB), ketamine, psilocybin, and others. The lysergic acid diethylamide segment accounted for a significant market share in 2020 and it is estimated that it will grow rapidly during the projected timeframe owing to its ability to increase social interaction, as per a study performed by Researchers from McGill University. Also, LSD is effective in reducing symptoms of stress-related anxiety and depression which in turn is also contributing to the growth of this segment.

"Amongst application, resistant depression to hold a significant share in the market in 2020"

Based on application, the psychedelic drugs market is classified into resistant depression, opiate addiction, post-traumatic stress disorder, panic disorders, and others. The resistant depression segment grabbed a significant market share in 2020. The growth of this segment can be attributed to the increase in the number of people not responding adequately to at least one antidepressant trial of adequate doses and duration.

"Amongst distribution channels, hospital pharmacies to hold a significant share in the market in 2020"

Based on distribution channels, the market is fragmented into hospital pharmacies, retail pharmacies, and others. Among these, the hospital pharmacies to hold a significant share in the market in 2020. This is mainly due to the increasing preference of the patients to avail treatment in hospitals and the easy availability of the medication in hospital pharmacies. Also, the tendency of consumers to visit hospital pharmacies for safe and authorized drugs is also driving the growth of this segment.

"North America to hold a significant share in the market"

For a better understanding of the market adoption of the psychedelic drugs industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. The major factors such as an increase in the population with mental disorders, a rise in investments in research and development for these drugs coupled with technological advancements and raising awareness regarding mental health among the population in the region. As per the National Institute of Mental Health (NIMH) statistics, in 2020, an estimated 52.9 million adults aged 18 or older in the United States had a mental illness.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

The global psychedelic drugs market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

1 MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Psychedelic Drugs Market
2.2. Research Methodology of the Psychedelic Drugs Market
2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE PSYCHEDELIC DRUGS MARKET

6 PSYCHEDELIC DRUGS MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY DRUGS

7.1. Lysergic Acid Diethylamide (LSD)
7.2. Gamma Hydroxybutyric Acid (GHB)
7.3. Ketamine
7.4. Psilocybin
7.5. Others

8 MARKET INSIGHTS BY APPLICATION

8.1. Resistant Depression
8.2. Opiate Addiction
8.3. Post-traumatic Stress Disorder
8.4. Panic Disorders
8.5. Others

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

9.1. Hospital Pharmacies
9.2. Retail Pharmacies
9.3. Others

10 MARKET INSIGHTS BY REGION

10.1. North America
- 10.1.1. U.S.
- 10.1.2. Canada
- 10.1.3. Rest of North America
10.2. Europe
- 10.2.1. Germany
- 10.2.2. U.K.
- 10.2.3. France
- 10.2.4. Italy
- 10.2.5. Spain
- 10.2.6. Rest of Europe
10.3. Asia-Pacific
- 10.3.1. China
- 10.3.2. Japan
- 10.3.3. India
- 10.3.4. Rest of Asia-Pacific
10.4. Rest of World

11 PSYCHEDELIC DRUGS MARKET DYNAMICS

11.1. Market Drivers
11.2. Market Challenges
11.3. Impact Analysis

12 PSYCHEDELIC DRUGS MARKET OPPORTUNITIES

13 PSYCHEDELIC DRUGS MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

14.1. Demand Side Analysis
14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

16.1. Competitive Landscape
- 16.1.1. Porters Fiver Forces Analysis

17 COMPANY PROFILED

17.1. Jazz Pharmaceuticals plc
17.2. Hikma Pharmaceuticals plc
17.3. Celon Pharma SA
17.4. Cybin Corp.
17.5. Pfizer Inc.
17.6. Numinus Wellness Inc.
17.7. F. Hoffmann-La Roche Ltd.
17.8. Avadel Pharmaceuticals PLC
17.9. PharmaTher Inc.
17.10. NRX Pharmaceuticals Inc.

18 DISCLAIMER

02-2729-4219

+886-2-2729-4219

License/价格

幻觉剂的全球市场:现状分析与预测(2022年～2028年)

Psychedelic Drugs Market: Current Analysis and Forecast (2022-2028)

目录

第1章市场简介

第2章调查方法或假设

第3章市场摘要

第4章摘要整理

第5章幻觉剂市场的COVID-19影响

第6章幻觉剂市场收益(2020年～2028年)

第7章市场洞察:各类医药品

第8章市场洞察:各用途

第9章市场洞察:各流通管道

第10章市场洞察:各地区

第11章幻觉剂市场动态

第12章幻觉剂市场机会

第13章幻觉剂市场趋势

第14章需求面和供给面的分析

第15章价值链分析

第16章竞争模式

第17章公司概要

第18章免责声明